<DOC>
	<DOCNO>NCT01776411</DOCNO>
	<brief_summary>Phase I portion : To confirm safety tolerability recurrent/refractory peripheral T-cell lymphoma patient repeat oral administration forodesine 300 mg twice daily ( 600 mg/day ) 28 day , determine recommend dose . Also , evaluate pharmacokinetics . Phase II portion : To evaluate efficacy , safety , pharmacokinetics recommend dosage regimen determine phase I portion . The primary efficacy endpoint shall objective response rate ( ORR ) .</brief_summary>
	<brief_title>Phase I/II Clinical Study Forodesine Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<criteria>Japanese patient least 20 year age . Patients histologically diagnosed peripheral Tcell lymphoma pathological diagnosis biopsied lesion . In study , peripheral Tcell lymphoma define following mature Tcell/NKcell neoplasms find 4th edition WHO Classification . Recurrent/refractory patient treatment history least one regimen . Patients enlarge lymph node extranodal mass lesion clearly measurable two perpendicular direction great 1.5 cm maximum diameter compute tomography perform . Patients expect survive least 3 month . ECOG PS 01 . Patients adequate hemopoietic efficacy , liver kidney function . Patients write consent obtain prior study initiation . Patients receive chemotherapy agent high dose systemic adrenocorticosteroid within 21 day prior initial administration study drug . Patients receive radiation therapy , phototherapy , electron beam therapy within 21 day prior initial administration study drug . Patients receive another study drug within 28 day prior initial administration study drug . Patients receive antibody therapy within 100 day prior initial administration study drug . Patients history allogeneic hematopoietic stem cell transplantation . Or patient history autologous hematopoietic stem cell transplantation within 100 day prior initial administration study drug . Patients cerebral metastasis central nervous system lesion past history . Patients active multiple primary cancer . Or patient history malignant neoplasm peripheral Tcell lymphoma within past 5 year . Patients severe cardiovascular disease . Patients congenital long QT syndrome . Patients QTcF &gt; 0.48 sec . Patients positive HBs antigen , HCV antibody HIV antibody immunological investigation . Or patient positive either HBc antibody HBs antibody , show DNA sensitivity HBVDNA assay . Patients positive CMV antigen immunological investigation . Patients infectious disease require treatment consist intravenous administration antibacterial agent , fungicide , antiviral drug . Patients interstitial pneumonia pulmonary fibrosis , patient judge insufficient pulmonary function .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>